6.6088

0.53% -0.1312

Vir Biotechnology Inc (VIR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché VIR Giù? Forum Previsione

Precedente Chiudi:

$6.74

Aprire:

$6.74

Volume 24 ore:

263.48K

Relative Volume:

0.28

Capitalizzazione di mercato:

$953.02M

Reddito:

$62.04M

Utile/perdita netta:

$-533.34M

Rapporto P/E:

-1.4719

EPS:

-4.49

Flusso di cassa netto:

$-473.07M

1 W Prestazione:

-22.41%

1M Prestazione:

-12.37%

6M Prestazione:

-34.34%

1 anno Prestazione:

-28.91%

Intervallo 1D:

$6.57

$6.81

Intervallo di 1 settimana:

$6.57

$8.71

Portata 52W:

$6.57

$13.09

Vir Biotechnology Inc Stock (VIR) Company Profile

Nome

Vir Biotechnology Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

415-906-4324

Indirizzo

1800 OWENS STREET, SAN FRANCISCO, CA

Dipendente

587

Cinguettio

@Vir_Biotech

Prossima data di guadagno

2024-10-31

Ultimi documenti SEC

VIR's Discussions on Twitter

Confronta VIR con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VIR	6.64	953.02M	62.04M	-533.34M	-473.07M	-4.49
VRTX	445.82	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.34	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	589.04	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.89	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.89	24.49B	3.30B	-501.07M	1.03B	11.54

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-01-29	Downgrade	JP Morgan	Overweight → Neutral
2023-09-08	Downgrade	BofA Securities	Buy → Neutral
2023-03-06	Aggiornamento	JP Morgan	Neutral → Overweight
2023-02-21	Aggiornamento	Goldman	Neutral → Buy
2023-01-27	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2022-09-14	Iniziato	SVB Leerink	Outperform
2022-09-09	Iniziato	Morgan Stanley	Underweight
2022-03-03	Aggiornamento	Robert W. Baird	Underperform → Neutral
2021-12-21	Downgrade	Robert W. Baird	Neutral → Underperform
2021-10-25	Aggiornamento	JP Morgan	Underweight → Neutral
2021-09-22	Downgrade	Goldman	Buy → Neutral
2021-06-04	Ripresa	Robert W. Baird	Neutral
2021-01-27	Downgrade	JP Morgan	Neutral → Underweight
2021-01-20	Reiterato	H.C. Wainwright	Buy
2020-10-05	Iniziato	BofA Securities	Buy
2020-09-14	Aggiornamento	Goldman	Neutral → Buy
2020-09-11	Aggiornamento	JP Morgan	Underweight → Neutral
2020-08-20	Iniziato	Needham	Buy
2020-03-19	Downgrade	JP Morgan	Neutral → Underweight
2020-03-13	Downgrade	Goldman	Buy → Neutral
2020-02-27	Downgrade	Robert W. Baird	Neutral → Underperform
2020-02-04	Downgrade	JP Morgan	Overweight → Neutral
2019-11-14	Iniziato	Robert W. Baird	Neutral
2019-11-05	Iniziato	Barclays	Overweight
2019-11-05	Iniziato	Cowen	Outperform
2019-11-05	Iniziato	Goldman	Buy
2019-11-05	Iniziato	JP Morgan	Overweight

Mostra tutto

Vir Biotechnology Inc Borsa (VIR) Ultime notizie

Nov 20, 2024

Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat

Nov 20, 2024

Empowered Funds LLC Decreases Stake in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat

Nov 20, 2024

Nov 19, 2024

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - BioSpace

Nov 19, 2024

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program - BioSpace

Nov 19, 2024

Nov 18, 2024

VIRVir Biotechnology, Inc. Latest Stock News & Market Updates - StockTitan

Nov 18, 2024

Vir's Hepatitis Delta Drug Achieves 100% Response Rate in Phase 2 Trial | VIR Stock News - StockTitan

Nov 18, 2024

EMA grants orphan drug status to Vir Biotech hepatitis treatments - Investing.com

Nov 18, 2024

EMA grants orphan drug status to Vir Biotech hepatitis treatments By Investing.com - Investing.com Canada

Nov 18, 2024

Vir Biotechnology (VIR) Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - StreetInsider.com

Nov 18, 2024

Vir Biotechnology Secures Key EU Orphan Drug Status for Hepatitis Delta Treatment | VIR Stock News - StockTitan

Nov 18, 2024

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD the Liver Meeting - Marketscreener.com

Nov 18, 2024

Nov 16, 2024

Vir Biotechnology (NASDAQ:VIR) Shares Down 7.4%Here's Why - MarketBeat

Nov 16, 2024

Nov 15, 2024

(VIR) Proactive Strategies - Stock Traders Daily

Nov 15, 2024

What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance

Nov 15, 2024

Promising hepatitis B treatment data presented by Vir Biotechnology - Investing.com

Nov 15, 2024